QPS expands their translational medicine capabilities at flagship facility in Delaware
QPS Holdings LLC (DE, USA), a CRO that provides testing services to support preclinical and clinical research and development, is expanding its technical personnel and laboratory capacity for translational medicine at its flagship Delaware Technology Park facility. It is hoped that this expansion will allow QPS to process high sample volumes required for Phase III clinical drug trials.
The company has projected an increase of laboratory staff from 57 to 88, with most of these additions being technical staff. It is predicted that the new investment will increase the number of analysis teams from seven to eleven and a new working group will be created focusing on neutralizing antibody assays.
The expansion plan further includes an increase in technical operations specifically immunobioanalysis, cell culture and protein mass spectrometry.
John Kolman, Global Head of Translational Medicine at QPS, concluded: “For a long time, clients have known us as the boutique CRO – a high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation. Now we are in a position to follow through and support Phase III, even for very large studies.”
